(Bloomberg) -- Lawmakers are seizing on last month's
study linking GlaxoSmithKline Plc's diabetes drug Avandia and
heart risks to press for new U.S. drug-safety legislation.
The study, released May 21, showed that Avandia, the world's
best-selling diabetes pill, increased the risk of a heart attack
43 percent. Members of Congress are questioning the Food and Drug
Administration's handling of evidence of side effects since the
drug won U.S. approval in 1999.
Read more at Bloomberg Exclusive News
study linking GlaxoSmithKline Plc's diabetes drug Avandia and
heart risks to press for new U.S. drug-safety legislation.
The study, released May 21, showed that Avandia, the world's
best-selling diabetes pill, increased the risk of a heart attack
43 percent. Members of Congress are questioning the Food and Drug
Administration's handling of evidence of side effects since the
drug won U.S. approval in 1999.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment